Literature DB >> 12898286

Dementia with Lewy bodies: disease concept and genetics.

Manuel B Graeber1, Ulrich Müller.   

Abstract

Dementia with Lewy bodies (DLB) was first recognized as a clinicopathological entity about 20 years ago. It is the second most-common degenerative dementia after Alzheimer's disease. Clinically, DLB differs from Alzheimer's disease in that disease symptoms are prone to fluctuate and patients often suffer from visual hallucinations, while short-term memory is relatively preserved. As many as 70% of patients have parkinsonism and up to 50% are sensitive to the extrapyramidal side effects of neuroleptic drugs. About 3 million Europeans will be affected by DLB in 2020 if no cure or effective treatment is found. This article reviews the current disease concept, as well as existing problems concerning classification and delineation of DLB from other conditions with dementia. The literature on genetic findings in this complex disease is critically discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12898286     DOI: 10.1007/s10048-003-0155-y

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  54 in total

1.  Selective hippocampal neuron loss in dementia with Lewy bodies.

Authors:  Antony J Harding; Bronwyn Lakay; Glenda M Halliday
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

Review 2.  Neurocardiovascular instability in cognitive impairment and dementia.

Authors:  Rose Anne M Kenny; Raj Kalaria; Clive Ballard
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

Review 3.  Dementia with Lewy bodies.

Authors:  James B Leverenz; Ian G McKeith
Journal:  Med Clin North Am       Date:  2002-05       Impact factor: 5.456

4.  Clinical and neuropathological correlates of Lewy body disease.

Authors:  Nozomi Hishikawa; Yoshio Hashizume; Mari Yoshida; Gen Sobue
Journal:  Acta Neuropathol       Date:  2003-01-14       Impact factor: 17.088

Review 5.  Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses.

Authors:  John Q Trojanowski; Virginia M Y Lee
Journal:  Neurotoxicology       Date:  2002-10       Impact factor: 4.294

6.  Tau-negative astrocytic star-like inclusions and coiled bodies in dementia with Lewy bodies.

Authors:  S Terada; H Ishizu; T Haraguchi; Y Takehisa; Y Tanabe; K Kawai; S Kuroda
Journal:  Acta Neuropathol       Date:  2000-11       Impact factor: 17.088

7.  The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions.

Authors:  R Egensperger; C Bancher; S Kösel; K Jellinger; P Mehraein; M B Graeber
Journal:  Biochem Biophys Res Commun       Date:  1996-07-16       Impact factor: 3.575

8.  The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease.

Authors:  C G Ballard; F Shaw; K Lowery; I McKeith; R Kenny
Journal:  Dement Geriatr Cogn Disord       Date:  1999 Mar-Apr       Impact factor: 2.959

9.  Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups.

Authors:  M Gearing; M Lynn; S S Mirra
Journal:  Arch Neurol       Date:  1999-02

10.  Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia.

Authors:  M G Martinoli; J Q Trojanowski; M L Schmidt; S E Arnold; T M Fujiwara; V M Lee; H Hurtig; J P Julien; C Clark
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more
  3 in total

1.  Twin pairs discordant for neuropathologically confirmed Lewy body dementia.

Authors:  C Sheei-Meei Wang; J R Burke; D C Steffens; C M Hulette; J C S Breitner; B L Plassman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

2.  Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease.

Authors:  Robert E Mrak; W Sue T Griffin
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

Review 3.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.